Telix Pharmaceuticals Lim... (TLX)
NASDAQ: TLX
· Real-Time Price · USD
10.23
-0.05 (-0.49%)
At close: Oct 06, 2025, 11:18 AM
Telix Pharmaceuticals Income Statement
Financials in AUD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 | Q2 2021 |
| Period Ending | Jun 30, 2025 | Dec 31, 2024 | Jun 30, 2024 | Dec 31, 2023 | Jun 30, 2023 | Dec 31, 2022 | Jun 30, 2022 | Dec 31, 2021 | Jun 30, 2021 |
Revenue | 1.19B | 783.21M | 470.68M | 502.55M | 356.88M | 160.1M | 28.73M | 7.6M | 6.52M |
Cost of Revenue | 513.22M | 273.53M | 122.82M | 187.76M | 221.18M | 130.78M | 63.16M | 37.63M | 25.95M |
Gross Profit | 674.14M | 509.68M | 347.86M | 314.79M | 135.7M | 29.32M | -34.43M | -30.03M | -19.43M |
Operating Income | 84.16M | 82.13M | 33.83M | 51.51M | 21.73M | -73.2M | -113.41M | -81.52M | -60.74M |
Interest Income | 10.25M | 10.86M | 1.18M | 1.02M | 667K | 215K | 90K | 163K | 93K |
Pretax Income | 39.57M | 56.06M | 24.53M | 3.09M | -40.22M | -98.62M | -132.7M | -99.04M | -72.2M |
Net Income | 34.76M | 49.92M | 31.21M | 5.21M | -47.51M | -104.08M | -118.89M | -80.51M | -59.1M |
Selling & General & Admin | 258.74M | 176.07M | 169.75M | 134.43M | 50.51M | 44.66M | 33.67M | 17.35M | 13.16M |
Research & Development | 199.21M | 121.03M | 144.18M | 128.84M | 63.46M | 57.86M | 45.31M | 34.13M | 28.15M |
Other Expenses | 132.03M | 130.45M | 96K | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 589.98M | 427.55M | 314.03M | 263.27M | 113.97M | 102.52M | 78.98M | 51.48M | 41.31M |
Interest Expense | 16.52M | 21.46M | 5.49M | 990K | 710K | 406K | 242K | 189K | 1.02M |
Selling & Marketing Expenses | 122.57M | 48.16M | 25.94M | 31.54M | 33.21M | 37.97M | 13.86M | 5.89M | 3.42M |
Cost & Expenses | 1.1B | 701.08M | 436.85M | 451.03M | 335.15M | 233.29M | 142.14M | 89.11M | 67.26M |
Income Tax Expense | 12.54M | 6.14M | -6.68M | -2.12M | 7.29M | 5.46M | -13.81M | -18.53M | -13.1M |
Shares Outstanding (Basic) | 337.21M | 331.23M | 334.23M | 323.73M | 317.62M | 316.34M | 307.33M | 283.02M | 281.02M |
Shares Outstanding (Diluted) | 337.2M | 345.19M | 350.75M | 323.73M | 317.62M | 316.34M | 307.33M | 283.02M | 281.02M |
EPS (Basic) | 0.11 | 0.15 | 0.10 | 0.02 | -0.15 | -0.33 | -0.4 | -0.29 | -0.22 |
EPS (Diluted) | 0.10 | 0.14 | 0.09 | 0.02 | -0.15 | -0.33 | -0.4 | -0.29 | -0.22 |
EBITDA | 85.71M | 117.09M | 63.28M | 57.72M | 27.68M | -67.8M | -108.04M | -76.07M | -55.38M |
EBIT | 76.7M | 92.55M | 34.99M | 9.04M | -39.51M | -98.22M | -132.45M | -98.58M | -70.91M |
Depreciation & Amortization | 8.67M | 1.66M | 5.75M | 5.38M | 5.94M | 5.4M | 5.37M | 5.44M | 5.36M |